University of Virginia Health System

Cardiology Grand Rounds
2005-06 ACADEMIC YEAR

---

Click the date of interest for complete information about that presentation. 

Sept       2005	6	13	20	27
Oct	4	11*	18	25
Nov	1	8	15	22	29
Dec	6	13	20	27
Jan         2006	3	10	17	24	31
Feb	7	14	21	28
Mar	7	14	21	28
Apr	4	11	18 #	25
May	2	9	16	23	30
June	6	13	20

 * 6th Annual Richard Savington Crampton Lectureship 
 # 23rd Annual Marjorie and Jaye Grollman Lectureship

---

  Sept. 6, 2005  

"Bypass Surgery vs. Angioplasty: 
Where Are We in 2005?"

George W. Vetrovec, M.D.
Professor of Medicine
Chairman, Cardiology Division, Department of Internal Medicine
Director, Adult Cardiac Catheterization Laboratory
Associate Chairman of Medicine for Clinical Affairs,
Medical College of Virginia/Virginia Commonwealth
University Health System
Richmond, Virginia

Biosketch
PubMed   

Learning Objectives:    Following the lecture, participants should be able to:

1. describe results of studies comparing percutaneous coronary intervention to bypass surgery.
2. discuss special subgroups such as patients with renal failure and left ventricular dysfunction relative to optimal revascularization strategies.

Disclosure: The speaker lists financial relationships with J&J/Cordis, Pfizer, Merck, and Lilly :  Disclosure

This activity is supported in part by an educational grant from Pfizer.

TOP

---

Sept. 13, 2005    

"The Role of Vasopressin and Vasopressin
Antagonistsin Heart Failure"

James E. Udelson, M.D.
Associate Professor of Medicine and Radiology
Associate Chief, Division of Cardiology, Department of Medicine,
Tufts University Medical School
Director, Nuclear Cardiology Laboratory
Co-Director, Heart Failure and Cardiac Transplant Center
Co-Director, Hypertrophic Cardiomyopathy Center
Tufts-New England Medical Center
Boston, Massachusetts

Biosketch
CV
PubMed

Learning Objectives:   Following the lecture, participants should be able to:

1. recognize the potential role of vasopressin in the pathophysiology in heart failure.
2. identify the role of neurohormonal blockade in congestive heart failure and the potential role of vasopressin receptor antagonism.
3. recall the current data regarding vasopressin antagonism in heart failure, as well as gain knowledge of the ongoing trials.
4. recognize the potential role of renal protection simultaneously with relief of congestion in decompensated heart failure.

Disclosure:  The speaker lists financial relationships with Otsuka Maryland Research, Astrellas, and GlaxoSmithKline:  Disclosure

This activity is supported in part by an educational grant from GlaxoSmithKline.

TOP

---

  Sept. 20, 2005  

"Should Revascularization Choices Change
in the Era of Drug-Eluting Stents?"

Spencer B. King, III, M.D., M.A.C.C.
Professor Emeritus, Emory University
School of Medicine Cardiology of Georgia
Fuqua Chair of Interventional Cardiology,
Fuqua Heart Center, Piedmont Hospital
Co-Director, American Cardiovascular Research Institute
Atlanta, Georgia

Biosketch
CV
PubMed  

Learning Objectives:   Following the lecture, participants should be able to:

1. identify the advantages and disadvantages of drug-eluting stents.
2. recognize the impact of drug-eluting stents over previous generation stents.
3. identify the role of drug-eluting stents in the choice of coronary artery bypass graft surgery vs percutaneous coronary intervention in multivessel disease, especially in diabetics.

Disclosure:  The speaker lists financial relationships with Novoste, Medtronic, and Bristol-Myers Squibb/Sanofi   Disclosure

This activity is supported in part by an educational grant from Bristol-Myers Squibb.

TOP

---

  Sept. 27, 2005  

CANCELLED

The program originally scheduled for this date (to have been presented by Andrew R. Marks, M.D.) has been moved to Feb. 28, 2006.

TOP

---

  Oct. 4, 2005  

"Advances in Cardiopulmonary Resuscitation"

Joseph P. Ornato, M.D.
Professor and Chairman,
Department of Emergency Medicine
Virginia Commonwealth University Health System
Richmond, Virginia

Biosketch
CV
PubMed 

Learning Objectives:   Following the lecture, participants should be able to:

1. identify controversies regarding uninterrupted chest compressions, use of fibrinolytics during resuscitation, avoidance of hyperventilation.
2. evaluate the use of circumferential chest compression devices during CPR.

Disclosure: The speaker discloses a financial relationship with: Revivant/Zoll.

This activity is supported in part by an educational grant from Genentech.

TOP

---

  Oct. 11, 2005  

THE 6th ANNUALRICHARD SAVINGTON CRAMPTON LECTURESHIP
IN CARDIOVASCULAR MEDICINE

Elizabeth G. Nabel, M.D.
Director, National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

  Biosketch
  PubMed

Learning Objectives:   Following the lecture, participants should be able to:

1. recall of the basic concepts of genomic medicine.
2. recognize new directions in translational research in cardiovascular disease.

For additional information on the Crampton Lectureship

TOP

---

  Oct. 18, 2005  

"The Changing Paradigm of Renal Artery Stenosis"

George A. "Rick" Stouffer, III, M.D.*
Harry A. Foscue Distinguished Professor of Medicine and Cardiology
Director of Interventional Cardiology
Director of Cardiac Catheterization Laboratories
Vice Chief of Cardiology for Clinical Affairs
Director, UNC Heart Center
University of North Carolina, Chapel Hill

* Dr. Stouffer received his postgraduate medical training at UVa, 7/87-6/95 (Internal Medicine Residency, Cardiovascular Research Fellowship, Clinical Cardiology Fellowship, and Interventional Cardiology Fellowship).

CV  
Website
Biosketch
PubMed

Learning Objectives:   Following the lecture, participants should be able to:

1. recognize the prevalence of renal artery stenosis in patients undergoing cardiac catheterization.
2. identify the mechanisms of obstructive renal artery stenosis.
3. recall ways to evaluate the significance of renal artery stenosis.
4. discuss ongoing clinical trials in the field of renal artery stenosis.

Disclosure: The speaker indicates that there are no financial relationships to report.

This activity is supported in part by an educational grant from The Medicines Company.

TOP

---

  Oct. 25, 2005  

"What Do We Really Know About the Management
of Decompensated Heart Failure?"

William T. Abraham, M.D.
Professor of Internal Medicine
Chief of Cardiovascular Medicine
Ohio State University Medical Center
Columbus, Ohio

Biosketch
Pubmed

Learning Objectives:   Following the lecture, participants should be able to:

1. describe the epidemiology of acute decompensated heart failure (ADHF)
2. recognize current evidence-based treatments of ADHF
3. develop an algorithm for ADHF treatment.

Disclosure:   A complete list of potential conflicts appears below:

Grants/research support: Amgen, Biotronick, CHF Solutions, GlaxoSmithKline, Heart Failure Society of America, National Institutes of Health, Medtronic Inc., Myogen Inc., Orqis Medical, Otsuka Maryland Research Institute, Paracor Inc., Scios Inc.
Consultant/speaker bureau: Amgen, AstraZeneca, Boehringer Ingelheim, CHF Solutions, GlaxoSmithKline, Guidant Corp., Medtronic Inc., Merck & Co. Inc., Pfizer, ResMed, Respironics, Scios Inc., St. Jude Medical
Advisory board memberships: CardioKine, CardioKinetix Inc., CHF Solutions, Department of Veterans Affairs Cooperative Studies Program, National Institutes of Health, Savacor Inc.
Honorarium recipient: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Guidant Corp., Medtronic Inc., Merck & Co Inc., Pfizer, ResMed, Respironics, Scios Inc., St. Jude Medical.
Editorial board involvement: Congestive Heart Failure, Current Cardiology Reviews, Current Heart Failure Reports, Expert Review of Cardiovascular Therapy, Journal Watch Cardiology, PACE-Pacing and Clinical Electrophysiology, The American Heart Hospital Journal, The Journal of Heart Failure.

"Coronary CT: A New Screening Test for CAD?"

Christopher M. Kramer, M.D.
Associate Professor, Departments of Radiology and Medicine;
Associate Chief, Cardiovascular Division;
Director, Cardiac Magnetic Resonance Imaging,
University of Virginia Health System

Learning Objectives:   Following the lecture, participants should be able to:

Disclosure: The speaker discloses financial relationships with: Siemens Medical Solutions, GE Healthcare, Astellas, and Novartis.

TOP

---

  Nov. 8, 2005  

"Beyond the New NCEP* Guidelines "

1. understand the relationship of PAI-1 and coronary disease
2. recall the mechanisms linking PAI-1 and vascular pathology
3. recognize the determinants of increased PAI-1 in obesity

1. recognize how the environment and routine of practice affects the quality of cardiac care.
2. describe efforts by the American College of Cardiology to overcome barriers to high quality care in practice.

Michael Landzberg, MD 
Founding Director 
Boston Adult Congenital Heart (BACH)
and Pulmonary Hypertension Service of the Children’s Hospital
and Brigham and Women’s Hospital, Boston
 Assistant Professor of Medicine, Harvard Medical School

Learning Objectives:    Following the lecture, participants should be able to:

1. Review the poor natural history of the post-infarct ventricular rupture.
2. Understand the importance of timing with respect to surgical approaches to post-infarct ventricular rupture, as well as  historical outcomes from this approach.
3. Review the novel percutaneous VSD occluder device techniques and outcomes.

Biosketch

"Endograft Management of Thoracic Aortic Diseases:  What’s New?"

Michael Dake, MD
Professor of Radiology
Chair, Department of Radiology
University of Virginia Health System

Learning Objectives:       

1. Review the range of thoracic aortic pathologies and the current indications for treatment
2. Understand the role of less invasive endovascular alternatives to open surgical repair of thoracic aortic lesions.
3. Review the results of stent-graft therapy for patients with thoracic aneurysm
4. Explore initial experiences with endografts for management of Type B aortic dissection
5. Become familiar with the limitation and complications of aortic stent-graft procedures

Biosketch

" Diagnosing and Treating Sleep Apnea"

1. recognize sleep apnea in patients
2. understand the relationship between sleep apnea and cardiovascular disease
3. effectively treat sleep apnea

1. recall new information on the causes and cures for heart failure and sudden cardiac death
2. apply this knowledge toward treatment

1. recall the relevant physiology of coronary flow reserve and methods by which it can be measured in the cardiac catheterization laboratory
2. evaluate the indications for the invasive assessment of flow reserve
3. recognize the limitations of non-invasive imaging in multi-vessel disease

"Impact of Time on Infarct Size
and Reperfusion Update" 

1. describe the role of duration on ischemia on infarct size 
2. discuss the role of myocardial infarction location on infarct size 
3. compare newer strategies to reduce infarct size

1. describe the process of atherothrombosis and the concept of the "vulnerable patient" versus the "vulnerable plaque"
2. discuss the exponential increase in risk for CVD with increasing numbers of risk factor
3. implement the current ACC/AHA guidelines for ACS in clinical practice
4. evaluate recently completed and ongoing trials that may impact future guidelines for acute care and chronic long-term preventive therapy for CVD

Learning Objectives:  By attending this presentation, learners should increase their ability to:

1. recognize the current limitations of evidence base for treatment decisions in valvular heart disease
2. recall and implement indications for aortic valve replacement in patients with aortic valve disease
3. recall and implement indications for mitral valve repair in patients with mitral regurgitation

  April 25, 2006

   

  May 2, 2006

   

Learning Objectives:   By attending this presentation, learners should increase their ability to: 

1. recall the clinical evidence and guidelines supporting PCI as primary reperfusion therapy for STEMI
2. recognize the "real world" difficulties in providing primary PCI as the dominant primary reperfusion strategy for STEMI
3. recall the rationale and evidence supporting the expansion of primary PCI outside of tertiary medical centers
4. recognize the prehospital therapeutic/triage strategies to minimize time to primary reperfusion strategy
5. recognize the rationale, potential, and difficulties in establishing STEMI centers which provide primary PCI on a regional basis

  May 23, 2006

   

Learning Objectives:   By attending this presentation, learners should increase their ability to:

TOP

---

  May 30, 2006
 

Learning Objectives:   By attending this presentation, learners should increase their ability to: 

1. implement cardiovacscular management in patients on hemodialysis

Learning Objectives:   By attending this presentation, learners should increase their ability to understand:

adenosine receptor pharmacology.
mechanisms of tissue protection by adenosine A_2A agonists.
clinical potential of A_2A agonists for myocardial infarction.

TOP

---

  June 20, 2006     

1. relationship of PAI-1 and coronary disease
2. mechanisms linking PAI-1 and vascular pathology
3. determinants of increased PAI-1 in obesity

---

Cardiology
Grand Rounds
Home

---

Monthly Events

---

Year-at-a-Glance

---

CME Requirements

---

Archives

---

Sponsored by:

Office of Continuing Medical Education of the University of Virginia School of Medicine